

## SHORT REPORT: MOLECULAR MARKERS ASSOCIATED WITH *PLASMODIUM FALCIPARUM* RESISTANCE TO SULFADOXINE-PYRIMETHAMINE IN THE DEMOCRATIC REPUBLIC OF CONGO

SANDRA COHUET, MARYLINE BONNET, MICHEL VAN HERP, CHANTAL VAN OVERMEIR,  
UMBERTO D'ALESSANDRO, AND JEAN-PAUL GUTHMANN\*

Epicentre, Paris, France; Médecins Sans Frontières, Brussels, Belgium; Prince Leopold Institute of Tropical Medicine, Antwerp, Belgium

**Abstract.** Sulfadoxine-pyrimethamine (SP) is the first line antimalarial treatment in the Democratic Republic of Congo. Using polymerase chain reaction, we assessed the prevalence of mutations in the *dihydrofolate reductase* (*dhfr*) (codons 108, 51, 59) and *dihydropteroate synthase* (*dhps*) (codons 437, 540) genes of *Plasmodium falciparum*, which have been associated with resistance to pyrimethamine and sulfadoxine, respectively. Four hundred seventy-four patients were sampled in Kilwa ( $N = 138$ ), Kisangani ( $N = 112$ ), Boende ( $N = 106$ ), and Basankusu ( $N = 118$ ). The proportion of triple mutations *dhfr* varied between sites but was always  $> 50\%$ . The proportion of *dhps* double mutations was  $< 20\%$ , with some sites as low as  $0.9\%$ . A quintuple mutation was present in  $12.8\%$  (16/125) samples in Kilwa;  $11.9\%$  (13/109) in Kisangani,  $2.9\%$  (3/102) in Boende, and  $0.9\%$  (1/112) in Basankusu. These results suggest high resistance to pyrimethamine alone or combined with sulfadoxine. Adding artesunate to SP does not seem a valid alternative to the current monotherapy.

Since 1997, the Democratic Republic of Congo (DRC) has been affected by continuous civil war, despite a 2003 cease-fire. With ongoing poor access to health care, the health status of the civilian population has continued to deteriorate. Since 2002, Médecins Sans Frontières (MSF) has supported health structures in areas neighboring the ceasefire line (Kisangani area in Oriental province, Boende and Basankusu areas in Equator province, and Kilwa area in Katanga; Figure 1), where access to the most vulnerable population is difficult. These are areas of perennial seasonal malaria affecting mainly small children. Malaria is one of the most significant health problems in these areas, accounting for 35% of all health center attendances in 2002 (Ministry of Health, unpublished data). The national protocol, adopted in October 2001, recommends sulfadoxine-pyrimethamine (SP) as the first-line treatment of uncomplicated malaria. However, resistance to this drug is expanding in many African countries.<sup>1,2</sup> Despite variable levels of SP resistance recently measured *in vivo*,<sup>3,4</sup> no data (*in vivo*, *in vitro*) were available for our intervention sites. In Kisangani and Basankusu, MSF used SP as the first-line treatment, whereas in Kilwa and Boende, a combination of SP and amodiaquine was used.

A good correlation has been shown between mutations in the *dihydrofolate reductase* (*dhfr*) and *dihydropteroate synthase* (*dhps*) genes of *Plasmodium falciparum* (*Pf*) and resistance to pyrimethamine and sulfadoxine, respectively.<sup>5,6</sup> Assessing the prevalence of *dhfr* and *dhps* mutations has been suggested as an alternative measure of SP resistance when *in vivo* studies are difficult to implement,<sup>7</sup> which was the case in our sites. We therefore determined the prevalence of the mutations in codons 51, 59, and 108 of the *dhfr* gene and in codons 437 and 540 of the *dhps* in each of our intervention sites. Triple mutations of the *dhfr* gene, double mutations of the *dhps* gene, and especially quintuple mutations of *dhfr* and *dhps* genes are strongly correlated *in vivo* with SP treatment failure.<sup>8,9</sup>

Authorization to conduct these analyses was given by the national health authorities. After obtaining written informed consent, a blood sample was collected from each patient presenting with uncomplicated malaria at Kisangani, Basankusu, Kilwa, and Boende health centers. All patients with *Pf* malaria confirmed both by a rapid test (Paracheck-Pf, Orchid, Goa, India) and a thick/thin smear had a second capillary blood smear collected on an Isocode stix (Schleicher & Schuell, Dassel, Germany) for genomic analysis. A minimum of 100 samples per health center (i.e., a total of 400 samples) was considered logistically manageable and sufficient to estimate the prevalence of the mutations. Samples were air dried, stored adequately, and transported to the Institute of Tropical Medicine (Antwerp, Belgium) where parasite DNA extraction and analysis of *dhfr* and *dhps* genes were performed. Mutation-specific nested polymerase chain reaction (PCR) and/or restriction digestions were used to analyze *dhfr* and *dhps* mutations as described elsewhere.<sup>10,11</sup> A detailed description of these methods is available at <http://www.medschool.umaryland.edu/CVD/plowe.html>.

The classification of samples was based on a published methodology.<sup>9</sup> In brief, each *dhfr* and *dhps* codon was characterized as wild-type (no mutation present), mixed (both wild and mutant genotypes clearly present in the same infection), or pure mutant (only mutant genotypes detected). Then, *dhfr* and *dhps* genotypes for each infection were categorized as follows: wild-type, no mutation detected; single, infection involving parasites with a single mutation; double, infection involving parasites with a double mutation; triple, infection involving parasites with all three mutations detected. Finally, infections involving parasites both with triple *dhfr* mutations and double *dhps* mutations were categorized as quintuple mutations.

Between September 2003 and March 2004,  $> 100$  samples were collected in each site, and most of them could be genotyped (Table 1). The proportion of triple mutations *dhfr* varied between sites but was always  $> 50\%$ . The proportion of *dhps* double mutations was much lower,  $< 20\%$ , with some sites as low as  $0.9\%$ . Overall, a quintuple mutation was present in  $12.8\%$  (16/125) of the samples in Kilwa;  $11.9\%$

\* Address correspondence to Jean-Paul Guthmann, Epicentre, 8 rue Saint Sabin, 75011 Paris, France. E-mail: jguthmann@epicentre.msf.org




FIGURE 1. Location (■) of health structures where the survey was carried out.

(13/109) in Kisangani; 2.9% (3/102) in Boende; and 0.9% (1/112) in Basankusu.

This survey provided an estimation of the SP resistance in different areas where *in vivo* test data were not available. Our sample was relatively small in size, because of the logistic difficulties. However, the confidence intervals are relatively narrow, allowing a fair estimate of the situation in the study sites. In our sites, the high frequency of *dhfr* triple mutations and the rather high frequency of *dhps* double mutations in two sites suggest that SP resistance is already well established. These findings are not surprising considering that SP resistance has been shown to increase quickly when used as monotherapy.<sup>12–14</sup> This situation could rapidly lead to low SP efficacy because of selection of resistant parasites by widespread

use of SP. Previous studies have suggested that they may be a stepwise accumulation of mutations in response to increasing drug pressure.<sup>15</sup> This could be also the case in our sites. However, the data presented here cannot confirm this hypothesis. It is important to note that differences between regions may also reflect variation in the duration and magnitude of SP use,<sup>16</sup> although these differences were not significant. This study on molecular markers associated with SP resistance should contribute to inform health authorities on anti-malarial efficacy in these sites and guide treatment policy. Indeed, in situations such as those we have described here, where *in vivo* tests cannot be carried out, the estimation of the prevalence of mutations offers an easy and rapid alternative. The prevalence of quintuple mutations varied from 12% to 1%; however, the information available (especially concerning the frequency and adequacy of antimalarial use in each site) does not provide a clear explanation for these differences between sites.

The implementation of artemisinin-based combinations (or ACT) recommended by WHO<sup>17</sup> needs careful consideration of the partner drug to be associated with the artemisinin component. The choice of new protocols should be seriously discussed among relevant authorities and malaria experts in DRC. The information provided here should be added and discussed considering other data available for the country. The high SP resistance suggested by our studies indicate that combining artesunate to SP would not increase the efficacy of the first-line treatment, at least not in the long term. Artemether + lumefantrine (Coartem, Novartis Pharma, Basel, Switzerland) has been shown to be very efficacious even in unsupervised conditions,<sup>18</sup> but one major limitation is the cost. At the current cost of 2.4 US\$/adult treatment, many African countries are unable to afford Coartem for public sector use without the support of international donors (e.g., the Global Fund). Artesunate + amodiaquine is another interesting alternative, less expensive than Coartem, and should

TABLE 1  
Prevalence of mutations at codons 108, 51, and 59 in *dhfr* and of mutations at codons 437 and 540 of *dhps*, by site

<i>Dhfr</i> *	Kilwa (n = 128)			Kisangani (n = 109)			Boende (n = 102)			Basankusu (n = 112)		
	n	%	95% CI	n	%	95% CI	n	%	95% CI	n	%	95% CI
Wild	5	3.9	1.4–9.3	3	2.8	0.7–8.4	3	2.9	0.6–8.3	1	1	0–5.6
Single mutation	4	3.1	1–8.3	0	0	–	2	2.0	0.2–6.9	5	4.5	1.6–10.6
Double mutation	19	14.8	9.4–22.5	43	39.4	30.3–49.3	35	34.3	25.2–44.4	33	29.4	21.4–38.9
Triple mutation	100	78.2	69.8–84.7	63	57.8	47.9–67.0	62	60.8	50.6–70.3	73	65.1	55.5–73.7
Mixte	49	38.4	29.9–47.3	35	32.1	23.7–41.8	44	43.1	33.4–53.3	64	57.1	47.4–66.3
Pure	51	39.8	34.4–48.9	28	25.7	18.0–35.1	18	17.6	10.8–26.4	9	8.0	3.9–15.1
<i>Dhps</i> †	Kilwa (n = 135)			Kisangani (n = 109)			Boende (n = 102)			Basankusu (n = 112)		
	n	%	95% CI	n	%	95% CI	n	%	95% CI	n	%	95% CI
Wild	102	75.6	62.3–82.4	62	56.9	47–66.2	30	29.4	20.8–39.2	38	34	25.4–43.5
Single mutation	15	11.1	6.6–17.9	26	23.8	16.4–33.1	68	66.7	56.6–75.7	73	65	55.5–73.8
Double mutation	18	13.3	8.3–20.5	21	19.3	12.6–28.2	4	3.9	1.1–9.7	1	0.9	0.0–5.6
Mixte	10	7.4	3.8–13.5	8	7.4	3.4–14.4	1	1.0	0.0–5.3	0	0	–
Pure	8	5.9	2.8–11.7	13	11.9	6.7–19.9	3	2.9	0.6–8.3	1	1	0.0–5.6
<i>Dhfr</i> + <i>dhps</i>	Kilwa (n = 125)			Kisangani (n = 109)			Boende (n = 102)			Basankusu (n = 112)		
	n	%	95% CI	n	%	95% CI	n	%	95% CI	n	%	95% CI
Quintuple mutation	16	12.8	7.7–20.2	8	7.3	3.4–14.3	3	2.9	0.6–8.3	1	0.9	0.0–5.6
Mixte	11	8.8	4.7–15.5	5	4.6	1.5–10.4	2	2	0.2–6.9	1	0.9	0.0–5.6
Pure	5	4	1.5–9.5	3	2.7	0.6–7.8	1	0.9	0.0–5.3	0	0	–

\* *Dhfr*: single = 108, 51, or 59, double = 108 and 51 or 59, triple = 108-51-59.

† *Dhps*: simple = 437 or 540, double = 437 and 540.

be soon available in blister packs as a fixed combination. Information available for amodiaquine<sup>19</sup> indicates that this drug is safe. Other promising alternatives (such as chlorproguanil-dapsone-artesunate, piperazine-dihydroartemisinin, or pyronaridine-artesunate) are currently under development and should soon become available, increasing considerably the options for the National Malaria Control Programs.

Received October 3, 2005. Accepted for publication February 9, 2006.

**Acknowledgments:** The authors thank Dr. Nsibu Ndosimao, General Director of the PNLP, for authorizing this study, Dr. Alphonse Swana-Nimy for representing PNLP on the field, and Dr. Kristina Persson and Dr. Anja Huefner who supervised the data collection on the field. We also thank Rebecca Freeman Grais at Epicentre headquarters for reviewing an earlier draft of the manuscript.

**Financial support:** This study was funded by Médecins sans Frontières. The American Society of Tropical Medicine and Hygiene (ASTMH) assisted with publication expenses.

**Authors' addresses:** Sandra Cohuet, Maryline Bonnet, and Jean-Paul Guthmann, Epicentre, 8 rue Saint Sabin, 75011 Paris, France. E-mails: sandra.cohuet@lshtm.ac.uk, maryline.bonnet@geneva.msf.org, and jguthmann@epicentre.msf.org; Michel van Herp, Médecins sans Frontières, 94 rue Dupré, 1090 Brussels, Belgium, E-mail: michel.vanherp@msf.be; Chantal van Overmeir and Umberto D'Alessandro, Prince Léopold Institute of Tropical Medicine, 155 Nationalestraat, B-2000 Antwerp, Belgium, E-mails: cvoverm@itg.be and udallessandro@itg.be.

**Reprints requests:** Jean-Paul Guthmann, Epicentre, 8 rue Saint Sabin, 75011 Paris, France. E-mail: jguthmann@epicentre.msf.org.

## REFERENCES

- MacArthur J, Stennies GM, Macheso A, Kolczak MS, Green MD, Ali D, Barat LM, Kazembe PN, Ruebush TK 2nd, 2001. Efficacy of mefloquine and sulfadoxine-pyrimethamine for the treatment of uncomplicated *Plasmodium falciparum* infection in Machinga District, Malawi, 1998. *Am J Trop Med Hyg* 65: 679–684.
- Ronn AM, Msangeni HA, Mhina J, Wernsdorfer WH, Bygbjerg IC, 1996. High level of resistance of *Plasmodium falciparum* to sulfadoxine-pyrimethamine in children in Tanzania. *Trans R Soc Trop Med Hyg* 90: 179–181.
- Kazadi WM, Vong S, Makina BN, Mantshumba JC, Kabuya W, Kebela BI, Ngimbi NP, 2003. Assessing the efficacy of chloroquine and sulfadoxine-pyrimethamine for treatment of uncomplicated *Plasmodium falciparum* malaria in the Democratic Republic of Congo. *Trop Med Int Health* 8: 868–875.
- Nsimba B, Malonga DA, Mouata AM, Louva K, Kiori J, Malanda M, Yocka D, Oko-Ossho J, Ebata-Mongo S, Le Bras J, 2004. Efficacy of sulfadoxine/pyrimethamine in the treatment of uncomplicated *Plasmodium falciparum* malaria in Republic of Congo. *Am J Trop Med Hyg* 70: 133–138.
- Kublin JG, Witzig RS, Shankar AH, Zurita JQ, Gilman RH, Guarda JA, Cortese JF, Plowe CV, 1998. Molecular assays for surveillance of antifolate-resistant malaria. *Lancet* 351: 1629–1630.
- Talisuna AO, Nalunkuma-Kazibwe A, Langi P, Mutabingwa TK, Watkins WW, Van Marck E, Egwang TG, D'Alessandro U, 2004. Two mutations in dihydrofolate reductase combined with one in the dihydropteroate synthase gene predict sulphadoxine-pyrimethamine parasitological failure in Ugandan children with uncomplicated falciparum malaria. *Infect Genet Evol* 4: 321–327.
- Nagesha HS, Din S, Casey GJ, Susanti AI, Fryauff DJ, Reeder JC, Cowman AF, 2001. Mutations in the pfmdr1, dhfr and dhps genes of *Plasmodium falciparum* are associated with in-vivo drug resistance in West Papua, Indonesia. *Trans R Soc Trop Med Hyg* 95: 43–49.
- Curtis J, Duraisingh MT, Warhurst DC, 1998. In vivo selection for a specific genotype of dihydropteroate synthetase of *Plasmodium falciparum* by pyrimethamine-sulfadoxine but not chlorproguanil-dapsone treatment. *J Infect Dis* 177: 1429–1433.
- Kublin JG, Dzinjalama FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RA, Rogerson SJ, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV, 2002. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of *Plasmodium falciparum* malaria. *J Infect Dis* 185: 380–388.
- Plowe CV, Cortese JF, Djimde A, Nwanyanwu OC, Watkins WM, Winstanley PA, Estrada-Franco JG, Mollinedo RE, Avila JC, Cespedes JL, Carter D, Doumbo OK, 1997. Mutations in *Plasmodium falciparum* dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. *J Infect Dis* 176: 1590–1596.
- Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE, 1995. Pyrimethamine and proguanil resistance-conferring mutations in *Plasmodium falciparum* dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. *Am J Trop Med Hyg* 52: 565–568.
- Wang P, Brobey RK, Horii T, Sims PF, Hyde JE, 1999. Utilization of exogenous folate in the human malaria parasite *Plasmodium falciparum* and its critical role in antifolate drug synergy. *Mol Microbiol* 32: 1254–1262.
- Terlouw DJ, Nahlen BL, Courval JM, Kariuki SK, Rosenberg OS, Oloo AJ, Kolczak MS, Hawley WA, Lal AA, Kuile FO, 2003. Sulfadoxine-pyrimethamine in treatment of malaria in Western Kenya: increasing resistance and underdosing. *Antimicrob Agents Chemother* 47: 2929–2932.
- Basco LK, 2003. Molecular epidemiology of malaria in Cameroon. XVI. Longitudinal surveillance of in vitro pyrimethamine resistance in *Plasmodium falciparum*. *Am J Trop Med Hyg* 69: 174–178.
- Nzila AM, Mberu EK, Sulo J, Dayo H, Winstanley PA, Sibley CH, Watkins WM, 2000. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in *Plasmodium falciparum*: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. *Antimicrob Agents Chemother* 44: 991–996.
- Alifrangis M, Enosse S, Khalil IF, Tarimo DS, Lemnge MM, Thompson R, Bygbjerg IC, Ronn AM, 2003. Prediction of *Plasmodium falciparum* resistance to sulfadoxine/pyrimethamine in vivo by mutations in the dihydrofolate reductase and dihydropteroate synthetase genes: a comparative study between sites of differing endemicity. *Am J Trop Med Hyg* 69: 601–606.
- World Health Organization. *Position of WHO's Roll Back Malaria Department on Malaria Treatment Policy*. Geneva: World Health Organization, 2003.
- Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E, Babigumira J, Kigozi I, Kiguli J, Kyomuhendo J, Ferradini L, Taylor W, Checchi F, Guthmann JP, 2005. Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated *Plasmodium falciparum* malaria in Mbarara, Uganda: a randomised trial. *Lancet* 365: 1467–1473.
- Olliaro P, Nevill C, LeBras J, Ringwald P, Mussano P, Garner P, Brasseur P, 1996. Systematic review of amodiaquine treatment in uncomplicated malaria. *Lancet* 348: 1196–1201.